Co-Author
This page shows the publications co-authored by Mark Pomerantz and Ji-Heui Seo.
Connection Strength
0.716
-
Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020 08; 52(8):790-799.
Score: 0.221
-
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Clin Cancer Res. 2022 Mar 01; 28(5):928-938.
Score: 0.062
-
Androgen receptor and MYC equilibration centralizes on developmental super-enhancer. Nat Commun. 2021 12 15; 12(1):7308.
Score: 0.061
-
Allele-specific epigenetic activity in prostate cancer and normal prostate tissue implicates prostate cancer risk mechanisms. Am J Hum Genet. 2021 11 04; 108(11):2071-2085.
Score: 0.060
-
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021 10 01; 12(1):5775.
Score: 0.060
-
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021 03 30; 12(1):1979.
Score: 0.058
-
Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 07; 26(7):1041-1043.
Score: 0.055
-
Evaluation of significant genome-wide association studies risk - SNPs in young breast cancer patients. PLoS One. 2019; 14(5):e0216997.
Score: 0.051
-
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell. 2018 07 12; 174(2):422-432.e13.
Score: 0.048
-
CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. Nat Med. 2015 Nov; 21(11):1357-63.
Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.